On the evening of March 2, Gan & Lee Pharmaceuticals announced that its independently developed Class 1 chemical new drug, GLR2037 tablets, received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA) for the treatment of advanced prostate cancer. This marks the first time Gan & Lee Pharmaceuticals has extended its R&D pipeline to the field of prostate cancer treatment, and it is also the company's first investigational product to enter the clinical stage on the emerging protein degradation targeted chimeric (PROTAC) technology platform.

According to the announcement, GLR2037 tablets are a Class 1 new chemical drug developed independently by Gan & Lee Pharmaceuticals , targeting a protein degradation chimeric antibody (AR PROTAC). Currently, no PROTAC products have been approved for marketing globally. It is understood that this drug selectively degrades target proteins related to disease pathogenesis by utilizing the cell's natural ubiquitin-proteasome system. Unlike traditional small molecule inhibitors, PROTAC technology holds promise for overcoming the common AR drug resistance problem in patients with advanced prostate cancer.

It is worth noting that the clinical trial application for GLR2037 tablets complies with the National Medical Products Administration's requirements for optimizing innovative drugs.The relevant requirements for clinical trial review and approval were included in the "30-day approval channel" for innovative drug clinical trials upon acceptance . This is Gan & Lee Pharmaceuticals' first investigational drug to enter this channel.

https://finance.eastmoney.com/a/202603033659923590.html